Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone

Journal of Orthopaedic Research

Volumn 21, Issue 1, 2003, Pages 62-72

  Lee, Y ^a   Schwarz, E ^b   Davies, M ^a   Jo, M ^a   Gates, J ^a   Wu, J ^a   Zhang, X ^a   Lieberman, J R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

Cytokines; Metastasis; Osteoblastic lesions; Osteoprotegerin; Prostate cancer

Indexed keywords

BONE; CYTOLOGY; HISTOLOGY; TUMORS;

OSTEOBLASTIC METASTASES;

CELLS;

BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 6; CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BONE DESTRUCTION; BONE METASTASIS; BONE RADIOGRAPHY; BONE REMODELING; CANCER CELL; CANCER TRANSPLANTATION; CARCINOGENESIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PATHOPHYSIOLOGY; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN SECRETION; REVIEW; THEORY; TIBIA;

EID: 0345831221     PISSN: 07360266     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0736-0266(02)00095-5     Document Type: Article

References (36)

1. Angelloz-Nicoud P, Binoux M. Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3). Endocrinology 1995;136:5485-92.
2. Boden S, McCuiag K, Hair G, Racine M, Titus L, Wozney J, et al. Differential effects and glucocorticoid potentiation of bone morphogenetic protein action during rat osteoblast differentiation in vitro. Endocrinology 1996;137:3401-7.
3. Capparelli C, Kostenuik P, Morony S, Starnes C, Weimann B, Van G, et al. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res 2000;60:783-7.
4. Carruba G, Leake R, Rinaldi F, Chalmers D, Comito L, Sorci C, et al. Steroid-growth factor interaction in human prostate cancer: short-term effects of transforming growth factors on growth of human prostate cancer cells. Steroids 1994;59:412-20.
5. Charhon S, Chapuy M, Delvin E, Valentin-Opran A, Edouard C, Meunier P. Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma with special reference to osteomalacia. Cancer 1983;51:918-24.
6. Chung T, Yu J, Spiotto M, Bartkowski M, Simons J. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 1999;38:199-207.
7. Clarke N, McClure J, George N. Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer. Brit J Urol 1992;69:64-70.
8. Clarke N, McClure J, George N. Morphometric evidence for bone resorption and replacement in prostate cancer. Brit J Urol 1991; 68:74-80.
9. Craft N, Chhor C, Tran C, Belldegrun A, Dekernion J, Witte O, et al. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res 1999;59:5030-6.
10. Culig Z, Hobisch A, Herold M, Hittmair A, Thurnher M, Eder I, et al. Interleukin 1β mediates the modulatory effects of monocytes on LNCaP human prostate cancer cells. Brit J Cancer 1998; 78:1004-11.
11. Cumming J, Hacking N, Fairhurst J, Ackery D, Jenkins J. Distribution of bony metastases in prostatic carcinoma. Brit J Urol 1990;66:411-4.
12. Festuccia C, Teti A, Bianco P, Guerra F, Vicentini C, Tennina R, et al. Human prostatic tumor cells in culture produce growth and differentiation factors active on osteoblasts: a new biological and clinical parameter for prostatic carcinoma. Oncol Res 1997;9:419-31.
13. Galasko C. Mechanisms of bone destruction in the development of skeletal metastases. Nature 1976;263:507-8.
14. Galasko C. Mechanisms of lytic and blastic metastatic disease of bone. Clin Orthop Relat Res 1982;169:20-7.
15. Goltzman D. Mechanisms of the development of osteoblastic metastases. Cancer 1997;80:1581-7.
16. Harris S, Harris M, Mahy P, Wozney J, Feng J, Mundy G. Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells. Prostate 1994;24:204-11.
17. Hofbauer L. Osteoprotegerin ligand and osteoprotergerin: novel implications for osteoclast biology and bone metabolism. Euro J Endocrinol 1999;141:195-210.
18. Hughes F, Collyer J, Stanfield M, Goodman S. The effects of bone morphogenetic protein-2, -4, and -6 on differentiation of rat osteoblast cells in vitro. Endocrinology 1995;136:2671-7.
19. Hullinger T, Taichman R, Linseman D, Somerman M. Secretory products from PC-3 and MCF-7 tumor cell lines upregulate osteopontin in MC3T3-E1 cells. J Cell Biochem 2000;78:607-16.
20. Ikeda I, Miura T, Kondo I. Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer. Brit J Urol 1996;77:102-6.
21. Jacobs S, Pikna D, Lawson R. Prostatic osteoblastic factor. Invest Urol 1979;17:195-8.
22. Jimi E, Akiyama S, Tsurukai T, Okahashi N, Kobayashi K, Udagawa N, et al. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J Immunol 1999;163:434-42.
23. Kaighn M, Narayan S, Ohnuki Y, Lechner J, Jones L. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979;17:16-23.
24. Kobayshi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, et al. Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000;191:275-85.
25. Koeneman K, Yeung F, Chung L. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999;39:246-61.
26. Koutsilieris M. Osteoblastic metastasis in advanced prostate cancer. Anticancer Res 1993;13:443-50.
27. Koutsilieris M, Rabbani S, Bennett H, Goltzman D. Characteristics of prostate-derived growth factors for cells of the osteoblast phenotype. J Clin Invest 1987;80:941-6.
28. Koutsilieris M, Rabbani S, Goltzman D. Effects of human prostatic mitogens on rat bone cells and fibroblasts. J Endocrinol 1987;115:447-54.
29. Lange P, Vessella R. Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer Metast Rev 1999;17:331-6.
30. Manolagas S. The role of IL-6 type cytokines and their receptors in bone. Ann New York Acad Sci 1998;840:194-204.
31. Michigami T, Ihara-Watanabe M, Yamazaki M, Ozono K. Receptor activator of nuclear factor κB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Cancer Res 2001;61:1637-44.
32. Royal R, Lange P, Vessella R. Preclinical models of prostate cancer. Semin Oncol 1996;23:35-40.
33. Schwarz EM, Benz E, Lu A, Goater J, Mollano A, Rosier R, et al. Quantitative small-animal surrogate to evaluate drug efficacy in preventing wear debris-induced osteolysis. J Orthop Res 2000; 18:849-55.
34. Taguchi Y, Yamamoto M, Yamate T, Lin S, Mocharla H, Detogni P, et al. Interleukin-6-type cytokines stimulate mesenchymal progenitor differentiation toward the osteoblastic lineage. Proc Assoc Amer Physicians 1998;110:559-74.
35. Takahashi N, Yamana H, Yoshiki S, Roodman G, Mundy G, Jones S, et al. Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology 1998;122:1373-82.
36. Zhang J, Dai J, Qi Y, Lin D, Smith P, Strayhorn C, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001;107:1235-44.